Transplant-associated thrombotic microangiopathy (TA-TMA) after hematopoietic cell transplantation is characterized by microangiopathic hemolytic anemia (MAHA) with persistent schistocytosis, elevated markers of hemolysis, thrombocytopenia, and microvascular thrombosis leading to ischemic injuries in the kidneys and other organs. The initial evaluation of the disease requires confirmation of non-immune MAHA and careful examination of known secondary causes of TMA. Due to increased likelihood of long-term renal failure and overall mortality, a rapid diagnosis and treatment of the underlying trigger is needed. However, the diagnostic criteria proposed to define TA-TMA remain insufficient. sC5b9, the soluble form of the membrane attack complex of the terminal complement pathway, is the most studied prognostic biomarker for the disease, though its sensitivity and specificity remain suboptimal for clinical use. Current evidence does not support the cessation of calcineurin inhibitors without cause or the use of therapeutic plasma exchange. Many recent single-arm studies targeting the complement pathway inhibition have been reported, and larger randomized controlled trials are ongoing. This review aims to provide an evidence-based discussion from both adult and pediatric perspectives on the advances and conundrums in TA-TMA diagnosis and treatment.

1.
Jodele
S
,
Laskin
BL
,
Dandoy
CE
, et al.
A new paradigm: diagnosis and management of HSCT-associated thrombotic microangiopathy as multi- system endothelial injury
.
Blood Rev
.
2015
;
29
(
3
):
191
-
204
.
2.
Li
A
,
Wu
Q
,
Davis
C
, et al.
Transplant-associated thrombotic microangiopathy is a multifactorial disease unresponsive to immunosuppressant withdrawal
.
Biol Blood Marrow Transplant
.
2019
;
25
(
3
):
570
-
576
.
3.
Story
CM
,
Gerber
GF
,
Chaturvedi
S.
Medical consult: aHUS, TTP? How to distinguish and what to do
.
Hematology Am Soc Hematol Educ Program
.
2023
;
2023
(
1
):
745
-
753
.
4.
Go
RS
,
Winters
JL
,
Leung
N
, et al
;
Mayo Clinic Complement Alternative Pathway-Thrombotic Microangiopathy Disease-Oriented Group
.
Thrombotic microangiopathy care pathway: a consensus statement for the Mayo Clinic Complement Alternative Pathway-Thrombotic Microangiopathy (CAP-TMA) Disease-Oriented Group
.
Mayo Clin Proc
.
2016
;
91
(
9
):
1189
-
1211
.
5.
George
JN
,
Li
X
,
McMinn
JR
,
Terrell
DR
,
Vesely
SK
,
Selby
GB
.
Thrombotic thrombocytopenic purpura-hemolytic uremic syndrome following allogeneic HPC transplantation: a diagnostic dilemma
.
Transfusion
.
2004
;
44
(
2
):
294
-
304
.
6.
Van Benschoten
V
,
Roy
C
,
Gupta
R
,
Ouellette
L
,
Hingorani
S
,
Li
A.
Incidence and risk factors of transplantation-associated thrombotic microangiopathy: a systematic review and meta-analysis
.
Transplant Cell Ther
.
2022
;
28
(
5
):
266.e1
-
266266.e8
.
7.
Gavriilaki
E
,
Sakellari
I
,
Anagnostopoulos
A
,
Brodsky
RA
.
Transplant-associated thrombotic microangiopathy: opening Pandora's box
.
Bone Marrow Transplant
.
2017
;
52
(
10
):
1355
-
1360
.
8.
Laskin
BL
,
Goebel
J
,
Davies
SM
,
Jodele
S.
Small vessels, big trouble in the kidneys and beyond: hematopoietic stem cell transplantation-associated thrombotic microangiopathy
.
Blood
.
2011
;
118
(
6
):
1452
-
1462
.
9.
Gavriilaki
E
,
Sakellari
I
,
Batsis
I
, et al.
Transplant-associated thrombotic microangiopathy: incidence, prognostic factors, morbidity, and mortality in allogeneic hematopoietic cell transplantation
.
Clin Transplant
.
2018
;
32
(
9
):
e13371
.
10.
Kraft
S
,
Bollinger
N
,
Bodenmann
B
, et al.
High mortality in hematopoietic stem cell transplant-associated thrombotic microangiopathy with and without concomitant acute graft-versus-host disease
.
Bone Marrow Transplant
.
2019
;
54
(
4
):
540
-
548
.
11.
Jodele
S
,
Davies
SM
,
Lane
A
, et al.
Diagnostic and risk criteria for HSCT-associated thrombotic microangiopathy: a study in children and young adults
.
Blood
.
2014
;
124
(
4
):
645
-
653
.
12.
Dandoy
CE
,
Rotz
S
,
Alonso
PB
, et al.
A pragmatic multi-institutional approach to understanding transplant-associated thrombotic microangiopathy after stem cell transplant
.
Blood Adv
.
2021
;
5
(
1
):
1
-
11
.
13.
Postalcioglu
M
,
Kim
HT
,
Obut
F
, et al.
Impact of thrombotic microangiopathy on renal outcomes and survival after hematopoietic stem cell transplantation
.
Biol Blood Marrow Transplant
.
2018
;
24
(
11
):
2344
-
2353
.
14.
Epperla
N
,
Li
A
,
Logan
B
, et al.
Incidence, risk factors for and outcomes of transplant-associated thrombotic microangiopathy
.
Br J Haematol
.
2020
;
189
(
6
):
1171
-
1181
.
15.
Li
A
,
Gupta
R
,
Amos
CI
, et al.
Thrombotic microangiopathy increases the risk of chronic kidney disease but not overall mortality in long-term transplant survivors
.
Transplant Cell Ther
.
2021
;
27
(
10
):
864.e1
-
864864.e5
.
16.
Heybeli
C
,
Sridharan
M
,
Alkhateeb
HB
, et al.
Characteristics of late transplant-associated thrombotic microangiopathy in patients who underwent allogeneic hematopoietic stem cell transplantation
.
Am J Hematol
.
2020
;
95
(
10
):
1170
-
1179
.
17.
Agarwal
S
,
Cortes-Santiago
N
,
Scheurer
ME
, et al.
Diffuse alveolar hemorrhage: an underreported complication of transplant associated thrombotic microangiopathy
.
Bone Marrow Transplant
.
2022
;
57
(
6
):
889
-
895
.
18.
Nusrat
S
,
Davis
H
,
MacDougall
K
,
George
JN
,
Nakamura
R
,
Borogovac
A.
Thrombotic microangiopathy after hematopoietic stem cell and solid organ transplantation: a review for intensive care physicians
.
J Intensive Care Med
.
2024
;
39
(
5
):
406
-
419
.
19.
Dvorak
CC
,
Higham
C
,
Shimano
KA
.
Transplant-associated thrombotic microangiopathy in pediatric hematopoietic cell transplant recipients: a practical approach to diagnosis and management
.
Front Pediatr
.
2019
;
7
:
133
.
20.
Jodele
S
,
Zhang
K
,
Zou
F
, et al.
The genetic fingerprint of susceptibility for transplant-associated thrombotic microangiopathy
.
Blood
.
2016
;
127
(
8
):
989
-
996
.
21.
Gavriilaki
E
,
Touloumenidou
T
,
Sakellari
I
, et al.
Pretransplant genetic susceptibility: clinical relevance in transplant-associated thrombotic microangiopathy
.
Thromb Haemost
.
2020
;
120
(
4
):
638
-
646
.
22.
Zhang
Z
,
Hong
W
,
Wu
Q
, et al.
Pathway-driven rare germline variants associated with transplant-associated thrombotic microangiopathy (TA-TMA)
.
Thromb Res
.
2023
;
225
:
39
-
46
.
23.
Chaturvedi
S
,
Braunstein
EM
,
Yuan
X
, et al.
Complement activity and complement regulatory gene mutations are associated with thrombosis in APS and CAPS
.
Blood
.
2020
;
135
(
4
):
239
-
251
.
24.
Gavriilaki
E
,
Chrysanthopoulou
A
,
Sakellari
I
, et al.
Linking complement activation, coagulation, and neutrophils in transplant-associated thrombotic microangiopathy
.
Thromb Haemost
.
2019
;
119
(
9
):
1433
-
1440
.
25.
Horváth
O
,
Kállay
K
,
Csuka
D
, et al.
Early increase in complement terminal pathway activation marker sC5b-9 is predictive for the development of thrombotic microangiopathy after stem cell transplantation
.
Biol Blood Marrow Transplant
.
2018
;
24
(
5
):
989
-
996
.
26.
Mezö
B
,
Horváth
O
,
Sinkovits
G
,
Veszeli
N
,
Kriván
G
,
Prohászka
Z.
Validation of early increase in complement activation marker sC5b-9 as a predictive biomarker for the development of thrombotic microangiopathy after stem cell transplantation
.
Front Med (Lausanne)
.
2020
;
7
:569291.
27.
Qi
J
,
Wang
J
,
Chen
J
, et al.
Plasma levels of complement activation fragments C3b and sC5b-9 significantly increased in patients with thrombotic microangiopathy after allogeneic stem cell transplantation
.
Ann Hematol
.
2017
;
96
(
11
):
1849
-
1855
.
28.
Wall
SA
,
Zhao
Q
,
Yearsley
M
, et al.
Complement-mediated thrombotic microangiopathy as a link between endothelial damage and steroid- refractory GVHD
.
Blood Adv
.
2018
;
2
(
20
):
2619
-
2628
.
29.
Li
A
,
Bhatraju
PK
,
Chen
J
, et al.
Prognostic biomarkers for thrombotic microangiopathy after acute graft-versus-host disease: a nested case- control study
.
Transplant Cell Ther
.
2021
;
27
(
4
):
308.e1
-
308308.e8
.
30.
Jodele
S
,
Dandoy
CE
,
Sabulski
A
, et al.
Transplantation-associated thrombotic microangiopathy risk stratification: is there a window of opportunity to improve outcomes?
Transplant Cell Ther
.
2022
;
28
(
7
):
392.e1
-
392392.e9
.
31.
Ma
S
,
Bhar
S
,
Guffey
D
, et al.
Prospective clinical and biomarker validation of the American Society for Transplantation and Cellular Therapy consensus definition for transplantation-associated thrombotic microangiopathy
.
Transplant Cell. Ther
.
2023
;
29
(
11
):
685.e1
-
685.e7
.
32.
Sartain
S
,
Shubert
S
,
Wu
M-F
,
Wang
T
,
Martinez
C.
The alternative complement pathway activation product Ba as a marker for transplant-associated thrombotic microangiopathy
.
Pediatr Blood Cancer
.
2020
;
67
(
3
):
e28070
.
33.
Okamura
H
,
Nakamae
H
,
Shindo
T
, et al.
Early elevation of complement factor Ba is a predictive biomarker for transplant-associated thrombotic microangiopathy
.
Front Immunol
.
2021
;
12
:
695037
.
34.
Xu
Z
,
Luo
C
,
Lai
P
, et al.
von Willebrand factor as a predictor for transplant- associated thrombotic microangiopathy
.
Clin Appl Thromb Hemost
.
2020
;
26
:1076029619892684.
35.
Zeisbrich
M
,
Becker
N
,
Benner
A
, et al.
Transplant-associated thrombotic microangiopathy is an endothelial complication associated with refractoriness of acute GvHD
.
Bone Marrow Transplant
.
2017
;
52
(
10
):
1399
-
1405
.
36.
Gloude
NJ
,
Khandelwal
P
,
Luebbering
N
, et al.
Circulating dsDNA, endothelial injury, and complement activation in thrombotic microangiopathy and GVHD
.
Blood
.
2017
;
130
(
10
):
1259
-
1266
.
37.
Pan
T
,
Qi
J
,
You
T
, et al.
Circulating heme oxygenase-1 and complement activation in transplant-associated thrombotic microangiopathy
.
Biol Blood Marrow Transplant
.
2019
;
25
(
8
):
1486
-
1491
.
38.
Rotz
SJ
,
Luebbering
N
,
Dixon
BP
, et al.
In vitro evidence of complement activation in transplant associated-thrombotic microangiopathy
.
Biol Blood Marrow Transplant
.
2017
;
23
(
3
):
S244
-
S245
.
39.
Schoettler
ML
,
Bhatt
H
,
Vasu
S.
A systematic review of diagnostic, prognostic, and risk blood and urine biomarkers of transplant-associated thrombotic microangiopathy
.
Front Immunol
.
2022
;
13
:1064203.
40.
Jodele
S
,
Sabulski
A.
Reeling in complement in transplant-associated thrombotic microangiopathy: you're going to need a bigger boat
.
Am J Hematol
.
2023
;
98
(
suppl 4
):
S57
-
S73
.
41.
Ho
VT
,
Cutler
C
,
Carter
S
, et al.
Blood and marrow transplant clinical trials network toxicity committee consensus summary: thrombotic microangiopathy after hematopoietic stem cell transplantation
.
Biol Blood Marrow Transplant
.
2005
;
11
(
8
):
571
-
575
.
42.
Schoettler
ML
,
Carreras
E
,
Cho
B
, et al.
Harmonizing definitions for diagnostic criteria and prognostic assessment of transplantation-associated thrombotic microangiopathy: a report on behalf of the European Society for Blood and Marrow Transplantation, American Society for Transplantation and Cellular Therapy, Asia-Pacific Blood and Marrow Transplantation Group, and Center for International Blood and Marrow Transplant Research
.
Transplant Cell Ther
.
2023
;
29
(
3
):
151
-
163
.
43.
Ruutu
T
,
Barosi
G
,
Benjamin
RJ
, et al
;
European Group for Blood and Marrow Transplantation; European LeukemiaNet
.
Diagnostic criteria for hematopoietic stem cell transplant-associated microangiopathy: results of a consensus process by an international working group
.
Haematologica
.
2007
;
92
(
1
):
95
-
100
.
44.
Cho
B-S
,
Min
C-K
,
Eom
K-S
, et al.
Clinical impact of thrombotic microangiopathy on the outcome of patients with acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation
.
Bone Marrow Transplant
.
2008
;
41
(
9
):
813
-
820
.
45.
Jodele
S
,
Dandoy
CE
,
Aguayo-Hiraldo
P
, et al.
A prospective multi- institutional study of eculizumab to treat high-risk stem cell transplantation- associated TMA
.
Blood
.
2024
;
143
(
12
):
1112
-
1123
.
46.
Hingorani
S.
Renal complications of hematopoietic-cell transplantation
.
N Engl J Med
.
2016
;
374
(
23
):
2256
-
2267
.
47.
Hingorani
SR
,
Seidel
K
,
Lindner
A
,
Aneja
T
,
Schoch
G
,
McDonald
G.
Albuminuria in hematopoietic cell transplantation patients: prevalence, clinical associations, and impact on survival
.
Biol Blood Marrow Transplant
.
2008
;
14
(
12
):
1365
-
1372
.
48.
Cho
B-S
,
Yahng
S-A
,
Lee
S-E
, et al.
Validation of recently proposed consensus criteria for thrombotic microangiopathy after allogeneic hematopoietic stem-cell transplantation
.
Transplantation
.
2010
;
90
(
8
):
918
-
926
.
49.
Schoettler
M
,
Lehmann
LE
,
Margossian
S
, et al.
Risk factors for transplant-associated thrombotic microangiopathy and mortality in a pediatric cohort
.
Blood Adv
.
2020
;
4
(
11
):
2536
-
2547
.
50.
Vasu
S
,
Bejanyan
N
,
Miller
EG
, et al.
TA-TMA is frequent, but not all TA-TMA is actionable in adult allogeneic HCT patients: a report from the MIDAS (microangiopathy, endothelial damage in adults undergoing stem cell transplantation) consortium
.
Transplant Cell Ther
.
2024
;
30
(
2
):
s19
.
51.
Uderzo
C
,
Bonanomi
S
,
Busca
A
, et al.
Risk factors and severe outcome in thrombotic microangiopathy after allogeneic hematopoietic stem cell transplantation
.
Transplantation
.
2006
;
82
(
5
):
638
-
644
.
52.
Oran
B
,
Donato
M
,
Aleman
A
, et al.
Transplant-associated microangiopathy in patients receiving tacrolimus following allogeneic stem cell transplantation: risk factors and response to treatment
.
Biol Blood Marrow Transplant
.
2007
;
13
(
4
):
469
-
477
.
53.
Zhang
R
,
Zhou
M
,
Qi
J
, et al.
Efficacy and safety of eculizumab in the treatment of transplant-associated thrombotic microangiopathy: a systematic review and meta-analysis
.
Front Immunol
.
2021
;
11
:
564647
.
54.
Svec
P
,
Elfeky
R
,
Galimard
J-E
, et al.
Use of eculizumab in children with allogeneic haematopoietic stem cell transplantation associated thrombotic microangiopathy - a multicentre retrospective PDWP and IEWP EBMT study
.
Bone Marrow Transplant
.
2023
;
58
(
2
):
129
-
141
.
55.
Jodele
S
,
Dandoy
CE
,
Lane
A
, et al.
Complement blockade for TA-TMA: lessons learned from a large pediatric cohort treated with eculizumab
.
Blood
.
2020
;
135
(
13
):
1049
-
1057
.
56.
Khaled
SK
,
Claes
K
,
Goh
YT
, et al
;
OMS721-TMA-001 Study Group Members
.
Narsoplimab, a mannan-binding lectin-associated serine protease-2 inhibitor, for the treatment of adult hematopoietic stem-cell transplantation-associated thrombotic microangiopathy
.
J Clin Oncol
.
2022
;
40
(
22
):
2447
-
2457
.
57.
Padmanabhan
A
,
Connelly-Smith
L
,
Aqui
N
, et al.
Guidelines on the use of therapeutic apheresis in clinical practice - evidence-based approach from the Writing Committee of the American Society for Apheresis: the eighth special issue
.
J Clin Apher
.
2019
;
34
(
3
):
171
-
354
.
58.
Yeates
L
,
Slatter
MA
,
Bonanomi
S
, et al.
Use of defibrotide to treat transplant-associated thrombotic microangiopathy: a retrospective study of the Paediatric Diseases and Inborn Errors Working Parties of the European Society of Blood and Marrow Transplantation
.
Bone Marrow Transplant
.
2017
;
52
(
5
):
762
-
764
.
59.
Martínez-Muñoz
ME
,
Forés
R
,
Lario
A
, et al.
Use of defibrotide to treat adult patients with transplant-associated thrombotic microangiopathy
.
Bone Marrow Transplant
.
2019
;
54
(
1
):
142
-
145
.
You do not currently have access to this content.